EyeGate Pharma Raises $22.6 Million
EyeGate Pharma, a Paris-based developer of iontophoresis technology to non-invasively deliver therapeutics for ocular indications, has raised $22.6 million in Series D funding (including an initial $11m calldown). Natixis Private Equity and Emerging Capital were joined by return backers Ventech, Innoven Partners and Medicis Capital. The company previously raised around $31 million.
8 January 2010•2 mins read
